Can-Fite BioPharma Ltd Stock News

Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel

Can-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.

As retail investors seek explosive returns, penny stocks remain enticing potential opportunities capable of massive short-term gains. However, the considerable risks of these cheap equities also highl

MTRX, OPI, CANF, ENLV and RAIL have been added to the Zacks Rank #1 (Strong Buy) List on October 27, 2023.

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncolog

Can-Fite's (CANF) shares rise 11.4% as it reveals its plans of submitting an investigational new drug application. The idea is to initiate expansion studies for namodenoson to treat pancreatic carcino

Can-Fite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Can-Fite BioPharma Ltd. NYSEAMERICAN: CANF is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers, inflammatory diseases and sexual dysfunction.

CanFite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Can-Fite BioPharma Ltd (NYSE: CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis. The study data show th

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022

Can-Fite BioPharma (CANF) said it received a notice of allowance from the U.S

Dr. Pnina Fishman CEO of Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) will deliver a poster presentation titled “Inhibition of Hepatocellular Carcinoma Growth and Liver Fibrosis by Nanomolar Cannabinoids Concentrations ” at the CannX Medical Cannabis Conference in Tel Aviv which takes place March 14 – 15, 2022. The abstract will additionally be published in the peer-reviewed scientific journal Medical Cannabis and Cannabinoids. Cannabinoids bind to CB1 and CB2 receptors regulating the function … Full story available on Benzinga.com

Gainers: Voyager Therapeutics VYGR +22%. 908 Devices (MASS) +16%. Viemed Healthcare VMD +10%

Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF ) said that the topline data from its Phase 3 Comfort study of Piclidenoson in severe plaque psoriasis would be released in Q2 2022 . Earlier, the data were anticipated in Q1 of 2022. The study enrolled more than 400 … Full story available on Benzinga.com